Company Description
Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries.
The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally.
The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States.
It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers.
The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.
| Country | Colombia |
| Founded | 2016 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 296 |
| CEO | Andres Fajardo |
Contact Details
Address: Bodega 19-b Parque Industrial Tibitoc Ph Tocancipa - Cundinamarca, F8 251017 Colombia | |
| Phone | 561-634-7430 |
| Website | cleverleaves.com |
Stock Details
| Ticker Symbol | CLVR |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001819615 |
| CUSIP Number | 186760104 |
| ISIN Number | CA1867602031 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andres Fajardo | Co-Founder, Chief Executive Officer and Director |
| Henry R. Hague III | Chief Financial Officer |
| Julian Wilches | Chief Regulatory Officer |
| Gustavo Escobar | Chief Operating Officer |
| Marta Pinto Leite | General Counsel and Corporate Secretary |
| Andrew Miller | Head of Business Development |
| Camilo Bohorquez | Head of Colombia |
| Caroline Kliess | Managing Director of Germany |
| Jackie Keshner | Investor Relations Executive |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 21, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 16, 2024 | 15-12G | Securities registration termination |
| May 15, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| May 8, 2024 | EFFECT | Notice of Effectiveness |
| May 6, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 6, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 6, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 6, 2024 | POS AM | Post-Effective amendments for registration statement |
| May 6, 2024 | 25 | Filing |
| Apr 26, 2024 | 8-K | Current Report |